Poonawalla has been getting threats from various groups regarding the COVID-19 vaccine supplies.
'We have just scratched the surface because cricket has been around for the longest time.'
Businessmen from all over the world attended Radhika Merchant and Anant Ambani's wedding at the Jio World Convention Centre, Bandra Kurla Complex, north west Mumbai, on Friday, July 12, 2024.
More screens, more films, and longer windows will convert to more people watching, assuming they know a film is releasing, points out Vanita Kohli-Khandekar.
Business tycoons at the Ambani's pre-wedding celebrations at Jamnagar, Gujarat.
Industry experts believe that this deal will positively impact the Indian film industry, which is struggling with fewer movie releases.
Billionaire Mukesh Ambani's Reliance Industries and Tata Group have made it to the prestigious TIME's list of 100 World's Most Influential Companies of 2024. TIME called Reliance 'India's Juggernaut'. This is the second time that Reliance has found its way into the TIME list. Jio Platforms, the firm that holds digital properties of the conglomerate, was included in the inaugural TIME 100 Most Influential Companies List of 2021. Serum Institute is the other Indian company on the list.
The development comes after requests for indemnity and exemption from bridging trials have been made by Pfizer and Moderna to the Indian government.
'I understand some people are comfortable getting a Covishield shot as their third dose.'
Serum Institute along with other vaccine producers have agreed with the government to sacrifice profits. There is no vaccine industry on the planet that has agreed to provide vaccines at such a subsidised price, he added.
Currently, Covishield and other COVID vaccines are approved for people above the age of 18 years.
Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection.
Dominic Xavier offers his take on the increasing number of COVID-19 cases in India as the citizens can hope and pray for the miracle of an early vaccine.
The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.
'Once DCGI will give us the permission to restart the trials in India, we will resume the trials,' Serum Institute of India (SII) said in a statement.
India's first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched in a few months and made available to the people in an affordable price range of Rs 200-400, Serum Institute of India CEO Adar Poonawalla said on Thursday.
Meet the best dressed celebs this week.
Vaccine major Serum Institute of India on Tuesday said the approval for the COVID-19 vaccine 'Covovax' would strengthen immunization initiatives across India and various lower and middle income countries across the world.
Confirming the Drugs Controller General Of India (DCGI) approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted: '@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly.'
SII's CEO Adar Poonawalla took to Twitter to announce the "philanthropic" gesture.
'We are trying to salvage 50-100 million doses of Covishield with the latest drive on booster doses.'
The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.
The study also noted that the booster dosage of the company's COVID-19 vaccine Vaxzevria also increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
Time's profile of Modi says that in its 74 years as an independent nation, India has had three pivotal leaders -- Jawaharlal Nehru, Indira Gandhi and Modi. "Narendra Modi is the third, dominating the country's politics like no one since them."
Adar Poonawalla said the real challenge lies in taking the vaccine to the "common man, to the vulnerable groups of people and to healthcare workers".
This will be an upfront payment for the vaccine doses that these two companies will supply to the government.
In a joint statement posted on their respective twitter accounts, the companies said Serum Institute Chief Executive Officer Adar Poonawalla and Bharat Biotech Chairman Krishna Ella communicated their combined intent to develop, manufacture and supply the COVID-19 vaccines.
Serum Institute has the capacity to make 250 million doses of Covishield monthly.
The prime minister was happy that the assurance given by the Serum Institute that it will make India self-sufficient in vaccines at the lowest possible price in the world was fulfilled.
The Serum Institute of India has informed the Centre that it will be able to supply around 22 crore doses of Covishield in October as the Union government has announced resuming export of surplus Covid vaccines in the coming fourth quarter under the 'Vaccine Maitri' programme, official sources said.
Serum Institute of India, the world's largest vaccine manufacturer, has a licence to produce the shot and has already manufactured close to 50 million doses.
Adar Poonawalla said he was hopeful that Covovax, the Novavax vaccine made by SII, will be launched around October this year for adults and for children by the first quarter of next year, depending on DCGI approvals.
The company has set an affordable ceiling price of USD 3 (around Rs 225) per dose, it added.
Pune-based Serum Institute of India (SII) is sitting on 200 million doses of Covishield that were manufactured in December and are set to expire in September. The company is likely to destroy these vaccines if nothing works out, Sohini Das reports.
The Covid-19 vaccine demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials, reports Sohini Das
What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.
On production capacity of Covishield, the vaccine being manufactured and supplied by Serum in India under a licensing agreement with Oxford and AstraZeneca, he said the present capacity is 130 million doses per month and always try to increase it further.
Poonawalla noted that reducing the timeframe would give "real relief" to the people who want to travel abroad.
The Covishield maker's forte throughout the past half a century has been a combination of affordable vaccines and high volumes. Its tetanus, diphtheria and measles vaccines are known throughout the world, reports Sohini Das.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances